CL2012001540A1 - Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina. - Google Patents

Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.

Info

Publication number
CL2012001540A1
CL2012001540A1 CL2012001540A CL2012001540A CL2012001540A1 CL 2012001540 A1 CL2012001540 A1 CL 2012001540A1 CL 2012001540 A CL2012001540 A CL 2012001540A CL 2012001540 A CL2012001540 A CL 2012001540A CL 2012001540 A1 CL2012001540 A1 CL 2012001540A1
Authority
CL
Chile
Prior art keywords
antibody
progestin
estrogen
antigen
antibodies
Prior art date
Application number
CL2012001540A
Other languages
English (en)
Inventor
Christiane Otto
Siegmund Wolf
Christoph Freiberg
Axel Harrenga
Simone Greven
Mark Trautwein
Sandra Bruder
Eicker
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001540(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2012001540A1 publication Critical patent/CL2012001540A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Anticuerpos o fragmento de unión a antígeno que antagoniza la señalización mediada por el receptor de prolactina; secuencia de ácido nucleico; composición farmacéutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrógeno y progestina.
CL2012001540A 2009-12-10 2012-06-08 Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina. CL2012001540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
CL2012001540A1 true CL2012001540A1 (es) 2013-01-18

Family

ID=42091520

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2012001540A CL2012001540A1 (es) 2009-12-10 2012-06-08 Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.
CL2012001539A CL2012001539A1 (es) 2009-12-10 2012-06-08 Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2012001539A CL2012001539A1 (es) 2009-12-10 2012-06-08 Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.

Country Status (40)

Country Link
US (6) US20120321632A1 (es)
EP (13) EP2332995A1 (es)
JP (7) JP2013513361A (es)
KR (2) KR101790366B1 (es)
CN (6) CN102947338B (es)
AP (1) AP2012006343A0 (es)
AR (6) AR079350A1 (es)
AU (2) AU2010330161B2 (es)
BR (1) BR112012015852B8 (es)
CA (6) CA2783678A1 (es)
CL (2) CL2012001540A1 (es)
CR (2) CR20120312A (es)
CU (2) CU23973B1 (es)
CY (2) CY1118209T1 (es)
DK (2) DK2510002T3 (es)
DO (2) DOP2012000160A (es)
EA (2) EA028678B1 (es)
EC (2) ECSP12011965A (es)
ES (2) ES2610654T3 (es)
GT (1) GT201200186A (es)
HK (2) HK1180354A1 (es)
HR (2) HRP20161401T1 (es)
HU (2) HUE031631T2 (es)
IL (2) IL220149A (es)
IN (2) IN2012DN05078A (es)
LT (2) LT2510006T (es)
MA (1) MA33888B1 (es)
ME (1) ME02577B (es)
MX (2) MX2012006621A (es)
NZ (2) NZ600511A (es)
PE (3) PE20171134A1 (es)
PL (2) PL2510006T3 (es)
PT (2) PT2510002T (es)
RS (2) RS55277B1 (es)
SG (2) SG181511A1 (es)
SI (2) SI2510002T1 (es)
TN (1) TN2012000294A1 (es)
TW (5) TW201130506A (es)
WO (6) WO2011069794A1 (es)
ZA (2) ZA201204213B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
SG10201709018QA (en) 2012-03-14 2017-11-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
TW201920245A (zh) * 2012-12-24 2019-06-01 美商艾伯維有限公司 催乳激素受體結合蛋白質及其用途
US20160002342A1 (en) * 2013-03-15 2016-01-07 Xinghang Ma Anti-prolactin receptor antibody formulations
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
WO2015168474A1 (en) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
KR20170105558A (ko) * 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
EP3722318A1 (en) 2015-07-06 2020-10-14 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
AU2017366873A1 (en) 2016-11-29 2019-06-13 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP2020519639A (ja) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置
EP3652205A1 (en) 2017-07-10 2020-05-20 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
RU2020129184A (ru) 2018-02-07 2022-03-09 Регенерон Фармасьютикалз, Инк. Способы и композиции для доставки терапевтического белка
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
ATE249840T1 (de) 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
EP0961616A4 (en) * 1996-09-13 2000-11-22 Trustees Of Board Of NON-HORMONAL CONTRACEPTIVE METHOD
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
EP1578480A2 (en) * 2002-12-13 2005-09-28 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
WO2006046689A1 (ja) * 2004-10-28 2006-05-04 Kyowa Hakko Kogyo Co., Ltd. 子宮内膜症治療剤
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
TWI454480B (zh) * 2006-08-18 2014-10-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
WO2009013621A2 (en) 2007-05-30 2009-01-29 Auckland Uniservices Limited Inhibitors for growth hormone and related hormones, and methods of use thereof
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
CN102858804A (zh) 2013-01-02
TWI487536B (zh) 2015-06-11
ZA201204213B (en) 2014-08-27
CA2783513A1 (en) 2011-06-16
AR079349A1 (es) 2012-01-18
CL2012001539A1 (es) 2012-10-12
EA201200851A1 (ru) 2013-01-30
TW201130504A (en) 2011-09-16
HK1180354A1 (en) 2013-10-18
EP2570436A1 (en) 2013-03-20
US20120315276A1 (en) 2012-12-13
SG181511A1 (en) 2012-07-30
US20130171147A1 (en) 2013-07-04
KR20120112527A (ko) 2012-10-11
SG181513A1 (en) 2012-07-30
DOP2012000160A (es) 2012-09-30
MX339343B (es) 2016-05-20
EP2567980A1 (en) 2013-03-13
PL2510002T3 (pl) 2017-02-28
PT2510006T (pt) 2017-01-20
HRP20170016T1 (hr) 2017-02-24
RS55277B1 (sr) 2017-02-28
AU2010330161B2 (en) 2015-07-09
CA2783610C (en) 2018-10-30
CU20120092A7 (es) 2012-10-15
EP2510002A1 (en) 2012-10-17
WO2011069795A1 (en) 2011-06-16
KR101765968B1 (ko) 2017-08-08
HUE030143T2 (en) 2017-04-28
US20130272968A1 (en) 2013-10-17
DK2510006T3 (en) 2017-01-23
JP2013513559A (ja) 2013-04-22
KR101790366B1 (ko) 2017-10-26
EP2332995A1 (en) 2011-06-15
ECSP12011966A (es) 2012-07-31
CN102884082A (zh) 2013-01-16
AP2012006343A0 (en) 2012-06-30
CN102858801A (zh) 2013-01-02
CN102858803A (zh) 2013-01-02
WO2011069796A1 (en) 2011-06-16
BR112012015852B8 (pt) 2021-05-25
WO2011069797A1 (en) 2011-06-16
BR112012015852A2 (pt) 2017-05-23
EP2510002B1 (en) 2016-08-24
JP6066474B2 (ja) 2017-01-25
AR079348A1 (es) 2012-01-18
CA2783513C (en) 2018-08-14
PL2510006T3 (pl) 2017-06-30
BR112012014048A2 (pt) 2017-10-31
CR20120312A (es) 2012-08-27
EP2510004A1 (en) 2012-10-17
WO2011069798A1 (en) 2011-06-16
EP2510006B1 (en) 2016-11-09
JP2013513363A (ja) 2013-04-22
BR112012015852A8 (pt) 2017-06-27
IL220149A (en) 2017-09-28
PE20121561A1 (es) 2012-11-25
JP2013513361A (ja) 2013-04-22
EA029327B1 (ru) 2018-03-30
TN2012000294A1 (en) 2013-12-12
CR20120310A (es) 2012-08-01
EA028678B1 (ru) 2017-12-29
IL220149A0 (en) 2012-07-31
CA2783514A1 (en) 2011-06-16
PE20121360A1 (es) 2012-10-11
EP2510007A1 (en) 2012-10-17
CN102741291A (zh) 2012-10-17
EP2510005A1 (en) 2012-10-17
TW201130507A (en) 2011-09-16
ES2610654T3 (es) 2017-04-28
JP2013513362A (ja) 2013-04-22
IL220151A0 (en) 2012-07-31
MA33888B1 (fr) 2013-01-02
HK1180700A1 (en) 2013-10-25
TW201130506A (en) 2011-09-16
US9241989B2 (en) 2016-01-26
DK2510002T3 (en) 2016-11-28
AU2010330165A1 (en) 2012-07-19
CY1118407T1 (el) 2017-06-28
JP2013513364A (ja) 2013-04-22
EP2567978A1 (en) 2013-03-13
EA201200860A1 (ru) 2013-01-30
WO2011069794A1 (en) 2011-06-16
CA2783610A1 (en) 2011-06-16
CU23973B1 (es) 2013-12-27
AR079352A1 (es) 2012-01-18
JP6199930B2 (ja) 2017-09-20
ES2603352T3 (es) 2017-02-27
MX2012006621A (es) 2012-10-05
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
CA2783654A1 (en) 2011-06-16
DOP2012000159A (es) 2012-09-30
PT2510002T (pt) 2016-11-23
US20130022606A1 (en) 2013-01-24
JP2015180690A (ja) 2015-10-15
JP2013513365A (ja) 2013-04-22
GT201200186A (es) 2014-01-06
NZ600511A (en) 2014-01-31
EP2510003A1 (en) 2012-10-17
CN102947338B (zh) 2015-11-25
CY1118209T1 (el) 2017-06-28
AU2010330161A1 (en) 2012-07-05
AR079351A1 (es) 2012-01-18
WO2011069799A1 (en) 2011-06-16
EP2567979A1 (en) 2013-03-13
BR112012015852B1 (pt) 2020-12-29
AR079641A1 (es) 2012-02-08
ECSP12011965A (es) 2012-07-31
PE20171134A1 (es) 2017-08-09
ZA201204214B (en) 2014-08-27
AR079350A1 (es) 2012-01-18
RS55589B1 (sr) 2017-06-30
HRP20161401T1 (hr) 2016-12-16
CA2783678A1 (en) 2011-06-16
IN2012DN05082A (es) 2015-10-09
MX2012006620A (es) 2012-06-21
TW201130505A (en) 2011-09-16
TW201138817A (en) 2011-11-16
TWI508744B (zh) 2015-11-21
SI2510006T1 (sl) 2017-02-28
US20120321632A1 (en) 2012-12-20
US20130129739A1 (en) 2013-05-23
NZ600512A (en) 2014-11-28
CN102947338A (zh) 2013-02-27
IN2012DN05078A (es) 2015-10-23
HUE031631T2 (en) 2017-07-28
AU2010330165B2 (en) 2015-07-16
CA2783651A1 (en) 2011-06-16
CU20120093A7 (es) 2012-10-15
SI2510002T1 (sl) 2016-12-30
EP2570435A1 (en) 2013-03-20
KR20120112528A (ko) 2012-10-11
WO2011069795A4 (en) 2011-08-18
LT2510006T (lt) 2016-12-12
CN102884082B (zh) 2015-05-20
US9649374B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
CL2012001540A1 (es) Anticuerpos o fragmento de union a antigeno que antagoniza la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratamiento combinado con estrogeno y progestina.
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
CL2012001650A1 (es) Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
AR081750A1 (es) Anticuerpos anti-cd40
CL2007002085A1 (es) Anticuerpo o fragmento del mismo especifico para el receptor epha2; polinucleotido que lo codifica; vector y celula huesped que lo comprenden; hibridoma; conjugados del mismo con agentes citotoxicos; composicion farmaceutica que los comprende;su uso
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CR20120371A (es) Antagonistas de pcsk9
CL2013000843A1 (es) Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
PE20150002A1 (es) Anticuerpos anti-fcrn
CL2019002686A1 (es) Formatos mejorados de receptor de unión a antígeno.
CR10298A (es) Metodos y composiciones para antagonismo de rage
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab